COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS AFFECTED BY CHRONIC KIDNEY DISEASE IN ITALY

被引：0
|
作者：
Di Costanzo, A. [1 ]
Uster, A. [2 ]
Vassallo, C. [1 ]
Fiorentino, F. [1 ]
机构：
[1] IQVIA Solut Srl, Milan, Italy
[2] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE117
引用
收藏
页码：S73 / S73
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS ANALYSIS OF USING KETOANALOGUES OF ESSENTIAL AMINOACIDS IN PATIENTS WITH CHRONIC KIDNEY DISEASE IN KAZAKHSTAN
    Avdeyev, A.
    Gulyaev, A.
    Akhmedullin, R.
    VALUE IN HEALTH, 2023, 26 (12) : S73 - S73
  • [42] Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial
    Reifsnider, Odette S.
    Kansal, Anuraag R.
    Wanner, Christoph
    Pfarr, Egon
    Koitka-Weber, Audrey
    Brand, Sarah B.
    Stargardter, Matthew
    Wang, Cheng
    Kuti, Effie
    Ustyugova, Anastasia
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2022, 79 (06) : 796 - 806
  • [43] Cost-effectiveness of ponatinib in chronic myeloid leukemia in Italy
    Lucioni, Carlo
    Iannazzo, Sergio
    Mazzi, Silvio
    Saporiti, Giorgia
    Chiroli, Silvia
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2015, 2 (01) : 1 - 16
  • [44] The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease
    Benjamin O. Yarnoff
    Thomas J. Hoerger
    Siobhan K. Simpson
    Alyssa Leib
    Nilka R. Burrows
    Sundar S. Shrestha
    Meda E. Pavkov
    BMC Nephrology, 18
  • [45] The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease
    Yarnoff, Benjamin O.
    Hoerger, Thomas J.
    Simpson, Siobhan K.
    Leib, Alyssa
    Burrows, Nilka R.
    Shrestha, Sundar S.
    Pavkov, Meda E.
    BMC NEPHROLOGY, 2017, 18
  • [46] A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy
    Colombo, Giorgio L.
    Gaeta, Giovanni B.
    Vigano, Mauro
    Di Matteo, Sergio
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2011, 3 : 37 - 46
  • [47] Population-Wide Screening for Chronic Kidney Disease A Cost-Effectiveness Analysis
    Cusick, Marika M.
    Tisdale, Rebecca L.
    Chertow, Glenn M.
    Owens, Douglas K.
    Goldhaber-Fiebert, Jeremy D.
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (06) : 788 - +
  • [48] Cost-effectiveness of sevelamer in the treatment of hyperphosphatemia associated with chronic kidney disease in Mexico
    Idrovo, J.
    Rivas, R.
    Zapata, L.
    VALUE IN HEALTH, 2008, 11 (03) : A301 - A301
  • [49] THE COST-EFFECTIVENESS OF PHOSPHATE BINDERS FOR THE TREATMENT OF HYPERPHOSPHATEMIA IN CHRONIC KIDNEY DISEASE (CKD)
    Keith, M. S.
    Carlton, R.
    Meissner, B. L.
    VALUE IN HEALTH, 2009, 12 (07) : A309 - A309
  • [50] Cost-effectiveness of screening for chronic kidney disease: existing evidence and knowledge gaps
    van Mil, Dominique
    Pouwels, Xavier G. L., V
    Heerspink, Hiddo J. L.
    Gansevoort, Ron T.
    CLINICAL KIDNEY JOURNAL, 2024, 17 (01)
12345